Recent News Articles
New study published in Frontiers of Aging included over 2,000 healthy adults over 70, and tracked relative cancer risk over five years. Participants were randomized to receive variations of vitamin D, omega-3, and home exercise.
According to a new study published in the Journal of Oncology, breast cancer patients treated in facilities offering integrative medicine support had better survival outcomes than patients treated in facilities that did not offer complementary treatment options.
For those of us living with cancer, this is what being proactive looks like right now in 4 steps. Because this is no time to lower your defenses.
Ed Yong’s recent sobering piece in The Atlantic on the U.S.’s lack of preparedness for the next pandemic that’s inevitably “barreling toward us” hit my inbox with a ‘must read’ thud. Cogently written, it provides historical context for the myriad errors committed—and how the many lessons learned early on with COVID were somehow not actionable for the next episode of death: the Delta variant.
A recent investigation commissioned by the Environmental Working Group identified imazalil and thiabendazole on nearly 90 percent of non-organic citrus fruit samples.
Recent studies show approximately one in four blood cancer patients fail to produce detectable antibodies after COVID-19 vaccination. This is most prevalent in those hosting non-Hodgkin lymphomas and chronic lymphocytic leukemia, but also in those hosting multiple myeloma and other blood cancers.
Advanced cancer care is the cornerstone of integrative oncology. Without conventional care, integrative oncology and lifestyle modifications are not complete. Here are the latest advances in cancer care during 2020.
Compelling new study indicates that the time of day we participate in physical activity can help fend off cancer.
There is good news in the advancement of chemo-free approaches to managing chronic lymphocytic leukemia, and I am thrilled to share it with you. Results of the phase III ECOG trial found that the combination of ibrutinib (Imbruvica) plus rituximab (Rituxan) came out superior to the chemotherapy and immunotherapy (chemoimmunotherapy) grouping of fludarabine, cyclophosphamide, and rituximab, known as FCR.
A recently published paper in the esteemed JAMA Oncology triggered dire headlines, including this one in The New York Times:
“People who used herbs, acupuncture and other complementary treatments tended to die earlier than those who didn’t.”
Really? Is this true?